ESTRO 2024 - Abstract Book

S5797

RTT - Education, training, advanced practice and role developments

ESTRO 2024

By week 3, over 50% of CSI patients experienced grade 1 fatigue which remained throughout treatment. For the dose escalated cohort, 78% of patients did not experience fatigue in the first two weeks. By week 3, 67% of this group experienced grade 1 fatigue from week 3 until the end of treatment. Of the CSI patients, 53% (n=10) were reviewed by the OT during their treatment and of the dose-escalated patients, 56% (n=5), saw the OT. Ninety-three percent of patients were provided with advice and recommendations regarding energy conservation techniques. A fatigue diary was provided to 67% of patients to support management of their experienced fatigue and 53% required support with sleep hygiene. Seventy percent of patients who received OT intervention in the CSI cohort reported an improved ability to complete their activities of daily living.

Skin erythema was documented for 18 of the 19 CSI patients. Results are shown in figure 1, whereby most patients in both groups experienced grade 0 skin toxicities.

Seventy nine percent (n=22) of the patients in both groups were referred to the dietician. Results are shown in figure 2. Clinically significant weight changes were noted in 18% (n=5) of patients within 3 months 3 . Of these 5 patients, 3 experienced clinically significant weight gain and 2 experienced weight loss. Replans were required for 2 dose escalated patients due to sinus filling, which the specialist neuro RTT could co-ordinate with the MDT for the patient. No replans were required for the CSI cohort.